Latest News


Latest News

Armonica Technologies Closes B Round Financing


Armonica Technologies, Inc., a biotechnology company developing a high throughput, direct long-read DNA sequencing technology, announced that it has raised $2M in new funding.  The financing included Hamamatsu Photonics K.K. and current investors Cottonwood Technology Fund, Sun Mountain Capital and Tramway Venture Partners. The funding will support further feasibility demonstration of company’s sequencing technology.

Akira Hiruma, President and CEO of Hamamatsu Photonics K.K., said, “At Hamamatsu, we are excited about our investment in Armonica, and their novel nanopore optical spectroscopy with its potential of new genetic sequencing methods to areas such as precision medicine. By investing in Armonica’s technology we hope to speed the development of new and more effective treatments to some of the world’s most devastating diseases.”

The Company’s CEO, Victor Esch, Ph.D. stated, “There continues to be an unmet clinical need for fast, high throughput long-read sequencing of native DNA, with an efficient workflow, that accurately identifies variants and epigenetics to enable clinical applications.  We are very excited about the progress the company has made in key areas of our technology, including the measurement of single nucleotide spectra.”

Armonica’s proprietary platform solves the fundamental challenges involved with traditional sequencing methodology, such as low speed and limited accuracy, by naturally controlling the speed of nucleic acid transport through nanochannels and reading single bases optically, without the need for library prep or adding biological constructs. Armonica’s optical readout technology is label free, has massive parallel capabilities, and can measure all epigenetic modifications directly. This unique approach to long-read sequencing will provide clinicians and researchers with a powerful tool that can detect previously unseen nuances and provide more accurate identification of genome variations and abnormalities.

About Armonica Technologies

Armonica Technologies is an Albuquerque, NM based biotechnology company focused on developing its proprietary long-read DNA sequencing technology. Armonica’s technology, optical nanopore sequencing, uses proprietary nanochannels to deliver long, single DNA molecules through nanopores, where characteristic optical signatures are read. Armonica’s approach will lead to faster, more thorough and more accurate genomic analysis than is currently available, without the need for extensive workflow and reagents. The Company’s innovative platform will enable clinicians to develop novel diagnostic tests that are based on complex variants including epigenetic modifications, and life science researchers to be more efficient and productive in their research and discovery capabilities.

 

Contact Information

info@armonicatech.com

Previous News

Armonica Technologies Awarded NIH Grant


Armonica Technologies, Inc., a biotechnology company developing a novel DNA sequencing system based on nano-structure devices, announced that the company has been awarded an SBIR grant from the NIH’s National Human Genome Research Institute for “Single molecule DNA/RNA transport and Raman scattering readout in a coupled nanochannel/nanopore sequencing system.” The award of $350K is in support of the company’s single molecule sequencing technology aimed at long read sequencing of large DNA molecules.

The company’s CSO Steve Brueck said, “long-read single-molecule sequencing that directly reads native DNA with epigenetic modifications, is considered the ideal solution for DNA sequencing research and clinical applications. Armonica’s unique technology is label and amplification free, and provides the exciting capability to read the optical spectra, or ‘spectral fingerprint’, of individual nucleotides including any epigenetic modifications.” As part of the award, Armonica is partnering with University of New Mexico through Jeremy Edwards’ high-throughput DNA sequencing laboratory in the department of Chemistry and Chemical Biology.

Armonica has demonstrated the ability to linearize and control the motion of single large molecules of single and double strand DNA, and has demonstrated single base sensitivity using a proprietary surface-enhanced Raman scattering (SERS) approach that is inexpensively integrated with its nanochannel/nanopore devices.

The company’s CEO, Victor Esch, stated, “Armonica continues to make significant improvements to the performance of our groundbreaking technology, and we are honored that the NIH has awarded us this grant in support of our product development goals.”

Armonica’s proprietary platform addresses the fundamental challenges involved with pore-based sequencing technologies, such as low throughput and limited accuracy, by naturally controlling the speed of nucleic acid transport through nanochannels and reading single base spectra optically, without the need for library preparations or biological manipulation. Armonica’s optical readout technology is label free, has massively parallel capabilities, and directly detects epigenetic nucleotide modifications. This unique approach will enable long-read sequencing and provide life science researchers with a powerful tool that can detect presently inaccessible nuances and provide more accurate identification of genome variations



Armonica Technologies has been selected to present a Flash Talk and two posters (Nanostructures for Long DNA Manipulation) | (Novel SERS Enhancement Structure for Sequencing) at the Advances in Genome Biology  and Technology General Meeting March 1-3, 2021.

Read More